Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Pituitary

• Publication date

  2011-01-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11102-010-0290-zPMID 21221817
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medical therapy of pituitary adenomas: Effects on tumor shrinkage

  2009cited by this paper
• Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients

  2008cited by this paper
• Quality of life in women with microprolactinoma treated with dopamine agonists

  2008cited by this paper
• Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea

  2008cited by this paper
• Diagnosis and management of hyperprolactinemia: expert consensus - French Society of Endocrinology.

  2007cited by this paper
• Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas

  2006influential reference
• Hyperprolactinaemia in 271 women: up to three decades of clinical follow‐up

  2005cited by this paper
• Cabergoline Therapy of Growth Hormone & Growth Hormone/Prolactin Secreting Pituitary Tumors

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.

  2003cited by this paper
• Dopamine receptor agonists for treating prolactinomas

  2002cited by this paper
• Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.

  2001influential reference
• Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.

  2001cited by this paper
• Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.

  2000influential reference
• Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.

  1999influential reference
• Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.

  1998cited by this paper
• Treatment of macroprolactinoma with cabergoline: a study of 85 patients

  1997cited by this paper
• [Treatment of hyperprolactinemic amenorrhea with cabergoline].

  1997cited by this paper
• [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].

  1995cited by this paper
• A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea

  1994cited by this paper
• Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study

  1992cited by this paper
• Osteocalcin levels in patients with microprolactinoma before and during medical treatment

  1990cited by this paper
• Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.

  1988cited by this paper
• Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.

  1986cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males

  year unknowncited by this paper

• Expression, Role, and Clinical Implications of P450 Aromatase Enzymes in the Pituitary Gland: A Scoping Review

  2026cites this paper
• Fertility and pregnancy in patients with prolactinoma.

  2026cites this paper
• Surgery for prolactinoma.

  2026cites this paper
• Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas.

  2026cites this paper
• Maternal dopamine agonist treatment before pregnancy reverses infertility and hyperprolactinemia in hCG-overexpressing mice through lactation: Evidence of generational effects.

  2025cites this paper
• Risk-Stratifying Pituitary Adenoma Treatment: A Cohort Analysis and Risk Prediction of Hypopituitarism

  2025influential citation
• Hook effect: a case study of a giant invasive prolactinoma in pregnancy with falsely low serum prolactin

  2025cites this paper
• Idiopathic hyperprolactinemia-associated hypogonadism in men presenting with normal testosterone levels

  2025cites this paper
• Idiopathic Hyperprolactinemia: Clinical Presentation, Diagnosis, Management, and Clinical Outcome

  2025influential citation
• Advances in Drug Treatments for Male Patients with Prolactinomas

  2025cites this paper
• Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM)

  2024cites this paper
• Medical therapy of pituitary adenomas

  2024cites this paper
• Disease activity and maternal-fetal outcomes in pregnant women with prolactinoma: A systematic review and meta-analysis.

  2024cites this paper
• The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis

  2024cites this paper
• Modulatory effect of vitamin B6 on sex hormone receptors, thyroid, and kisspeptin/kiss1r system in the uterus of pseudopregnant bitches.

  2024cites this paper
• Hyperprolactinemia in women: treatment

  2024cites this paper
• Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment

  2024cites this paper
• Mini review of the pathogenesis, incidence, and treatment of Pituitary adenomas

  2023cites this paper
• The Effect of Antipsychotics on Prolactinoma Growth: A Radiological and Serological Analysis

  2023cites this paper
• Linea guida per la terapia dei prolattinomi

  2023cites this paper
• Hyperprolactinemia-induced acute ischemic stroke.

  2023cites this paper
• Hypothalamic-Pituitary-Gonadal Axis Disorders Impacting Fertility in Both Sexes and the Potential of Kisspeptin-Based Therapies to Treat Them.

  2023cites this paper
• Development of a Guideline for Antipsychotic-induced Hyperprolactinemia in Korea Using the ADAPTE Process

  2023cites this paper
• Dopamine 2 agonists for the management of type 2 diabetes: a systematic review and meta-analysis

  2023cites this paper
• Italian Guidelines for the Management of Prolactinomas

  2023cites this paper
• How to manage intolerance to dopamine agonist in patients with prolactinoma

  2023cites this paper
• The Role of Aromatase Inhibitors in Male Prolactinoma

  2023cites this paper
• Rational Evaluation and Treatment of Prolactinomas: A Concise Review

  2022cites this paper
• Case Report: Hyperprolactinemia In Suprasellar Meningioma

  2022cites this paper
• Dopaminergic treatment of patients with acromegaly: still kicking after all these years

  2022cites this paper
• Prolactinoma: Medical and Surgical Considerations.

  2022cites this paper
• Non-surgical Interventions for Pituitary Lesions.

  2022cites this paper
• Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors

  2022cites this paper
• Peripartum Cardiomyopathy with the Cardiac Function Restored by Cabergoline

  2022cites this paper
• Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy

  2022cites this paper
• Prolactinoma: Clinical Characteristics, Management and Outcome

  2022cites this paper
• Effect of Dopaminergic Therapy on Impulse Control Disorders in Patients With a Prolactinoma

  2022cites this paper
• Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option

  2021cites this paper
• PROLACTIN AND HYPERPROLACTINAEMIA IN FEMALE REPRODUCTIVE ENDOCRINOLOGY – AN UPDATE

  2021cites this paper
• Effectiveness of Medical Treatment of Cushing’s Disease: A Systematic Review and Meta-Analysis

  2021cites this paper
• Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta‐analysis

  2021cites this paper
• Commentary: “Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery”

  2021cites this paper
• The Role of Dopamine Agonists in Pituitary Adenomas.

  2020cites this paper
• The Efficacy of Using Cabergoline in Psychogenic Erectile Dysfunction Treatment (A Local Study)

  2020cites this paper
• Cabergoline as an adjuvant to standard heart failure treatment in peripartum cardiomyopathy: A case report and review of the literature

  2020cites this paper
• Predictors of the Response to Dopaminergic Therapy in Patients with Prolactinoma.

  2020cites this paper
• Erratum. The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study.

  2020cites this paper
• Fertility issues in aggressive pituitary tumors

  2020cites this paper
• Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus

  2020cites this paper
• The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: A systematic review with meta analysis and trial sequential analysis of randomized clinical trials

  2020cites this paper
• Dopamine agonists in prolactinomas: when to withdraw?

  2019cites this paper
• Visual Loss

  2019cites this paper
• Prolactin and Its Role in Human Reproduction

  2019cites this paper
• Clinical management of difficult to treat macroprolactinomas

  2019cites this paper
• Management of pituitary incidentaloma.

  2019cites this paper
• Prolactin-Secreting Pituitary Adenomas: Clinical Management

  2019cites this paper
• Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women

  2019influential citation
• Prolactinomas in Children and Adolescents

  2019cites this paper
• Management of Pituitary Adenomas Invading the Cavernous Sinus.

  2019cites this paper
• The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study.

  2019cites this paper
• Dopamine agonist resistant prolactinomas: any alternative medical treatment?

  2019cites this paper
• Prolactinomas

  2019cites this paper
• Hyperprolactinémie

  2019cites this paper
• Management of prolactinoma: a survey of endocrinologists in China

  2018cites this paper
• Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm

  2018cites this paper
• Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review

  2018cites this paper
• Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series.

  2018cites this paper
• [Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists].

  2018cites this paper
• Prolaktinoma’lı Olgularımızın Klinik Değerlendirilmesi

  2018cites this paper
• Cabergoline versus Quinagolide for the Management of Macroprolactinoma and Erectile Dysfunction: A Randomized, Open-Label Study

  2018cites this paper
• Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism

  2018cites this paper
• Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics.

  2017cites this paper
• A whole animal chemical screen approach to identify modifiers of intestinal neutrophilic inflammation

  2017cites this paper
• Hyperprolactinaemia – a problem in patients from the reproductive period to the menopause

  2017cites this paper
• Electronic survey of management of hyperprolactinemia in Brazil: Endocrinologists versus gynecologists

  2017cites this paper
• Comparison Between Bromocriptine and Cabergoline Drugs as a Treatment of Hyperprolactinemia Among Sudanese Infertile Amenorrhic Women

  2016cites this paper
• Cabergoline or bromocriptine for prolactinoma?

  2016cites this paper
• Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.

  2016cites this paper
• Management of hormone-secreting pituitary adenomas

  2016cites this paper
• Differential diagnosis and management of abnormal uterine bleeding due to hyperprolactinemia

  2016cites this paper
• Efficacy and Mechanism of Action of Yiru Tiaojing Granule Against Hyperprolactinemia In Vitro and In Vivo

  2015cites this paper
• Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia

  2015cites this paper
• Neonatal formulary 7

  2015cites this paper
• Retrospective analyses of clinical and laboratory features of 646 patients with prolactinoma in Turkey

  2015cites this paper
• Bromocriptine (Parlodel) and Cabergoline (Dostinex)

  2015cites this paper
• Does Twice-weekly Cabergoline Improve Anthropometrical and Biochemical Profiles in Prediabetes? A Randomized Double-blind Clinical Trial Pilot Study

  2015cites this paper
• Current indications for the surgical treatment of prolactinomas.

  2015cites this paper
• Treatment of hyperprolactinemia in post-menopausal women: pros

  2015cites this paper
• A 17-year-old female with secondary amenorrhea, galactorrhea, and headaches.

  2015cites this paper
• Management of Medication-Related Adverse Effects

  2014cites this paper
• Guía de práctica clínica para el diagnóstico y tratamiento de la hiperprolactinemia

  2014cites this paper
• Chapter 13 - Drugs that Affect Autonomic Functions or the Extrapyramidal System

  2014cites this paper
• The Evaluation and Treatment of Delayed Ejaculation.

  2014cites this paper
• Cabergoline use and risk of fibrosis and insufficiency of cardiac valves

  2013cites this paper
• Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences

  2013cites this paper
• Current treatment options for hyperprolactinemia

  2013cites this paper
• Pharmacoeconomic aspects of the treatment of pituitary gland tumours

  2013cites this paper
• Pituitary tumors.

  2012cites this paper
• Short-Term Pharmacological Suppression of the Hyperprolactinemia of Infertile hCG-Overproducing Female Mice Persistently Restores Their Fertility

  2012cites this paper
• Hyperprolactinemia as a Rare Cause of Hypertension in Chronic Renal Failure

  2012cites this paper